CBD, CBG, CBN, and CBC all showed anti-melanoma activity against A375 cells, while CBN uniquely inhibited both mushroom and murine tyrosinase — suggesting potential applications in skin cancer and hyperpigmentation.
Read this if you are interested in cannabinoid-based skincare products or the anti-cancer properties of minor phytocannabinoids.
CBN uniqueCBN was the only cannabinoid to inhibit both mushroom and murine tyrosinase enzymes
What the researchers found
Among three melanoma cell lines, A375 cells were highly susceptible to all four phytocannabinoids (IC50 12.02-25.13 µg/mL). In melanin-producing B16F10 cells stimulated with αMSH, CBD, CBG, and CBN significantly reduced both extracellular and intracellular melanin content at 5 µg/mL. CBN uniquely inhibited both mushroom and murine tyrosinase. CBG and CBC inhibited only mushroom tyrosinase. CBD was inactive against tyrosinase, suggesting the anti-melanogenic effects of CBD, CBG, and CBN work through mechanisms other than direct tyrosinase inhibition.
Why it matters
This is the first study to evaluate CBN and CBC for anti-melanoma and anti-melanogenic properties, expanding the potential cosmeceutical and therapeutic applications of minor cannabinoids beyond CBD.
The numbers in context
- A375 melanoma IC50: 12.02-25.13 µg/mL across all 4 cannabinoids
- CBD, CBG, CBN reduced extracellular melanin to 29.76-45.14% at 5 µg/mL
- Intracellular melanin: 60.59-67.87% at 5 µg/mL
- CBN: inhibited both mushroom and murine tyrosinase (50-200 µg/mL)
- CBD: inactive against tyrosinase
How the study worked
In vitro study testing CBD, CBG, CBN, and CBC against three human melanoma cell lines and murine melanoma B16F10 cells. αMSH-induced melanogenesis model. Mushroom and murine tyrosinase inhibition assays.
Who was studied
In vitro melanoma cell lines and tyrosinase assays
What this study cannot tell us
In vitro only — cannot predict in vivo anti-cancer or skin-lightening efficacy. Concentrations used may not be achievable in skin. Only three melanoma cell lines tested. No human skin models used.
How to read the evidence
In vitro preliminary study. First data on CBN and CBC in melanoma and melanogenesis, but far from clinical application.
When this study was published
Published in 2023. Expands cannabinoid dermatology research beyond CBD.
The bigger picture
The cosmeceutical and dermatological applications of minor cannabinoids are largely unexplored. This study provides preliminary data suggesting CBN in particular could have dual applications in both anti-melanoma and anti-hyperpigmentation products.
Questions still open
- Would topical CBN formulations be effective for hyperpigmentation in human skin?
- Do these anti-melanoma effects translate to animal models?
- Could combinations of minor cannabinoids enhance anti-cancer efficacy?
Read the original research
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.
Pharmaceuticals (Basel, Switzerland), 16(5)
Citation
Gaweł-Bęben, Katarzyna; Czech, Karolina; Luca, Simon Vlad. (2023). Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.. Pharmaceuticals (Basel, Switzerland), 16(5). https://doi.org/10.3390/ph16050648